Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially assessing the progression of the condition.
iLCT provides template for drug repurposing in other conditions
The International Linked Clinical Trials programme (iLCT) is one of the largest drug repurposing initiatives in medical research. A recent review article provides an overview of the history, structure and progress of this successful programme.
Van Andel Institute: Virtual public lecture series
This informative event featured presentations and a Q&A session with international Parkinson’s disease experts including Cure Parkinson’s Director of Research, Dr Richard Wyse and Deputy Director of Research, Dr Simon Stott.
A skin test for Parkinson’s
Researchers have been investigating a waxy substance on our skin (called sebum) as a possible way of determining who does or does not have Parkinson’s.
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the venglustat clinical trial to assess changes in the course of the disease.